Category

• Pipeline2
• Business1

Organizations

• Bausch + Lomb64
• Eyes On Eyecare42
• Alcon, Inc.41
• American Optometric Association34
• Harrow26
• Glaukos25
• Regeneron21
• Aldeyra Therapeutics20
• Sight Sciences19
• American Academy Of Ophthalmology18

Tags

• Clinical Trials3
• Presbyopia3
• Presbyopia Eye Drops3
• Cataract1
• Geographic Atrophy1
• Merger1
• Preservative-free1

• Organizations: Visus Therapeutics✕

Clear all

Business

Tenpoint and Visus Therapeutics merge with plans for ophthalmic therapeutic advancements

Newly-combined Tenpoint Therapeutics, Ltd includes a pipeline featuring BRIMOCHOL PF, a once-daily eye drop for presbyopia targeting an NDA filing in 2025.

Pipeline

Visus releases topline data from phase 3 trial of Brimochol PF

BRIO-I trial successfully meets prespecified FDA primary endpoints.

Pipeline

Visus completes enrollment for phase 3 trial of Brimochol PF for presbyopia

Pivotal study is assessing safety and efficacy of the combined, fixed-dosage of carbachol and brimonidine tartrate.